Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?

被引:4
|
作者
Basu, Maya [1 ]
Balachandran, Aswini [1 ]
Duckett, Jonathan [1 ]
机构
[1] Medway Maritime Hosp, Dept Urogynaecol, Windmill Rd, Gillingham ME7 5NY, Kent, England
关键词
Afferent function; Mirabegron; Urodynamics; BETA(3)-ADRENOCEPTOR AGONIST; BETA-3-ADRENOCEPTOR AGONIST; URODYNAMIC VERIFICATION; AFFERENT ACTIVITY; DETRUSOR; INCONTINENCE;
D O I
10.1007/s00192-015-2809-3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction and hypothesis The aim of this study was to evaluate for any association between pretreatment cystometry results and outcome of treatment with mirabegron in women with overactive bladder (OAB) symptoms. Methods This was a prospective observational study of women with OAB symptoms that proved refractory to conservative management. All women underwent filling and voiding subtraction cystometry prior to further treatment. Women were treated with mirabegron 50 mg once daily, and outcomes were evaluated after 6 weeks' treatment. The primary outcome measure was change in symptoms as indicated by response to the Patient Global Impression of Improvement (PGI-I) scale. The presence of detrusor overactivity (DO), the highest detrusor pressure recorded during the filling phase, the presence of urodynamic stress incontinence (USI), cystometric capacity, voided volume, maximum flow rate and detrusor pressure at maximum flow were all compared between responders and nonresponders. Results The study population consisted of 169 women; response rate to mirabegron was 69.8 %. There was no association between the presence of DO or maximum detrusor pressure during filling and USI, cystometric capacity, maximum flow rate and detrusor pressure at maximum flow and treatment response. In a subgroup with OAB symptoms refractory to previous treatment with antimuscarinics, there was an association between the presence of DO and a positive treatment response (p = 0.02). Conclusions Overall, there is no association between urodynamic findings and response to treatment with mirabegron. This may reflect the fact that mirabegron's mode of action mechanisms are not measurable using cystometry. In women with refractory symptoms, however, the presence of DO is associated with a positive response to treatment.
引用
收藏
页码:427 / 431
页数:5
相关论文
共 50 条
  • [1] Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?
    Maya Basu
    Aswini Balachandran
    Jonathan Duckett
    International Urogynecology Journal, 2016, 27 : 427 - 431
  • [2] DOES AGE AFFECT THE EFFICACY OF MIRABEGRON IN WOMEN WITH OVERACTIVE BLADDER SYMPTOMS?
    Khalil, A.
    Balachandran, A.
    Curtiss, N. L.
    Duckett, J.
    Basu, M.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2017, 28 : S138 - S138
  • [3] THE EFFICACY AND SAFETY OF MIRABEGRON ON URINARY SYMPTOMS AND SEXUAL DYSFUNCTION IN WOMEN WITH OVERACTIVE BLADDER SYNDROME
    Gubbiotti, Marilena
    Serati, Maurizio
    Giannantoni, Antonella
    JOURNAL OF UROLOGY, 2019, 201 (04): : E381 - E382
  • [4] Mirabegron improves not only urinary symptoms but also sexual dysfunction in women with overactive bladder syndrome
    Gubbiotti, Marilena
    Giannantoni, Antonella
    Serati, Maurizio
    NEUROUROLOGY AND URODYNAMICS, 2019, 38 : S21 - S22
  • [5] The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
    Gubbiotti, Marilena
    Giannantoni, Antonella
    Cantaluppi, Simona
    Coluccia, Anna Chiara
    Ghezzi, Fabio
    Serati, Maurizio
    BMC UROLOGY, 2019, 19 (1)
  • [6] The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
    Marilena Gubbiotti
    Antonella Giannantoni
    Simona Cantaluppi
    Anna Chiara Coluccia
    Fabio Ghezzi
    Maurizio Serati
    BMC Urology, 19
  • [7] A NOVEL β3-ADRENOCEPTOR AGONIST MIRABEGRON FOR OVERACTIVE BLADDER SYMPTOMS
    Okada, Hiroshi
    Sato, Ryo
    Nishio, Kojiro
    Kawaguchi, Makoto
    Soh, Shigehiro
    Arai, Gaku
    JOURNAL OF UROLOGY, 2013, 189 (04): : E564 - E564
  • [8] Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort
    Peyronnet, Benoit
    Vurture, Gregory
    Palma, Jose-Alberto
    Malacarne, Dominique R.
    Feigin, Andrew
    Sussman, Rachael D.
    Biagioni, Milton C.
    Palmerola, Ricardo
    Gilbert, Rebecca
    Rosenblum, Nirit
    Frucht, Steven
    Kaufmann, Horacio
    Nitti, Victor W.
    Brucker, Benjamin M.
    PARKINSONISM & RELATED DISORDERS, 2018, 57 : 22 - 26
  • [9] The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry
    van Brummen, HJ
    Heintz, APM
    van der Vaart, CH
    NEUROUROLOGY AND URODYNAMICS, 2004, 23 (01) : 38 - 42
  • [10] Associations between subjective overactive bladder symptoms and objective parameters on bladder diary and filling cystometry
    N. M. P. Daan
    K. J. Schweitzer
    C. H. van der Vaart
    International Urogynecology Journal, 2012, 23 : 1619 - 1624